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The alkylating agent busulphan is commonly used as a single
agent for the treatment of chronic myeloid leukaemia
(CML). Patients receiving busulphan treatment for CML
ultimately relapse since the malignant clone is not eradicated.
Alternative treatments are clearly needed (Koller & Miller,
1986).
Combining two active drugs with different modes of
action can sometimes result in enhanced therapeutic efficacy
(Chang et al., 1979). Analysis of data obtained from
experiments to study this effect has been greatly facilitated
with the computer program developed by Chou & Chou
(1987), which is based on the median effect plot and multiple
drug equation derived by Chou & Talalay (1984).
A recent report showed that quercetin enhanced the anti-
proliferative activity of the alkylating agent nitrogen mustard
(Hofmann et al., 1988). Quercetin is a naturally occurring
flavonoid which inhibits a wide range of enzymes including
protein kinase C (PKC) (Gschwendt et al., 1983), the
tyrosine kinase encoded by the src oncogene (Graziani et al.,
1983), and other tyrosine kinases (Srivastava & Chiasson,
1986). PKC and several tyrosine kinases are located in or
near the cell membrane and are involved in the transduction
of growth factor signals to the nucleus. These enzymes
therefore represent novel therapeutic targets for anti-cancer
agents. Cells from patients with CML express an abnormal
tyrosine kinase (Maxwell et al., 1987) and the cells also
contain high levels of PKC (Helfman et al., 1983). We have
therefore investigated the effect of combining the protein
kinase inhibitor quercetin with busulphan on the
proliferation of the CML-derived cell line K562 (Lozzio &
Lozzio, 1975).
K562 cells were grown at 37°C in RPMI 1640 medium
containing fetal calf serum (10%), glutamine (2mM),
penicillin (100 units ml- ) and streptomycin (100l g ml- )
under an atmosphere of 5% CO2 in air. Cells were incubated
with various concentrations of busulphan, quercetin or the
two drugs in combination. Drugs were dissolved in DMSO
and sterilised by filtration before addition to the tissue
culture medium (the final concentration of DMSO was not
more than 0.5%). Drugs were freshly made up for each
experiment. After 5 days the cells were harvested and the
viable cell number was determined by trypan blue exclusion.
The ID50, ID70 and ID90 values for quercetin alone and
busulphan alone were 59, 106 and 265 pM and 13, 50 and
404pM respectively, as determined from dose-response
curves generated by the dose-effect analysis computer
program (Figure 1).
The effects of mixtures of quercetin and busulphan on
K562 cell proliferation were determined from median effect
plots of different concentrations of the two drugs singly and
combined in fixed ratios. These effects were quantitated in
terms of the 'combination index' (CI) (Chou & Chou, 1987).
CI= 1 indicates summation, CI<1 indicates synergism, and
CI> 1 indicates antagonism. In order to compensate for
variability between experiments, dose-response curves for
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both individual drugs and mixtures were determined within a
single experiment. Analysis of the data for quercetin and
busulphan combined in a ratio of 1:1 indicated that the two
drugs acted synergistically over a fractional effect range of
0.75-0.95 (75-95% cell kill) (Figure 2). The data have been
analysed under mutually non-exclusive conditions since we
have made the assumption that the two drugs are acting at
different targets. Similar results were obtained when the data
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Figure 1 Dose-response curves of K562 cells treated with
busulphan (0) or quercetin (0). Viable cell number was
determined by trypan blue exclusion 5 days after treatment. Data
represent the means (± s.d.) of three experiments.
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Figure 2 Effect of quercetin and busulphan combined 1:1 and
3:1 on K562 cell proliferation. Data were analysed under
mutually non-exclusive conditions (see text). Data represent the
means of three experiments.
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were analysed under mutually exclusive conditions (i.e. the
two drugs are assumed to act at the same site; data not
shown). Increasing the ratio of quercetin:busulphan to 3:1
enhanced the synergism over the fractional effect range of
0.45-0.95 (Figure 2). The ID50, ID70 and ID9 values for the
1:1 mixture and 3: 1 mixture were 28, 60 and 204IiM, and
25, 53 and 182pM respectively. Thus 18pM quercetin
combined with 6 JM busulphan was as effective as 13gM
busulphan in causing 50% inhibition of K562 proliferation.
Although the maximum tolerated dose for quercetin in
humans has not been determined, plasma concentrations of
12 pM quercetin were achieved following an intravenous
infusion of 100 mg without any apparent side effects (Gugler
et al., 1975). Interestingly, PKC inhibitors, of which
quercetin is an example, may be effective against normally
drug resistant cells (Wiesenthal et al., 1987; Fine et al.,
1988). This property, together with the anti-proliferative
effects of PKC inhibitors (O'Brian et al., 1986), makes them
attractive for development as anti-cancer agents either for
use on their own or in combination with conventional
cytotoxic drugs.
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